trial

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

NCTId NCT07122895
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Recruiting
Enrollment 90 (estimated)
Sponsored by China Medical University Hospital
Primary completion 2029-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Recruiting
Enrollment
90 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2025-09-16
Primary completion
2029-12
Eligibility
ALL · 20 Years · 65 Years

Interventions & indications

Drugs
NMDAE

Sponsors

China Medical University HospitalLead Sponsor
National Science and Technology Council, TaiwanCollaborator

Sites

1 total
Taichung, Taiwan

Linked catalysts

1
Sex Differences in NMDA-enhancing Treatment of Schizophrenia — primary completion2029-12

Facts & assertions

4 sourced
Enrollment
90
Phase
PHASE2
Primary Completion Date
2029-12
Status
RECRUITING
relationships
The graph out of here
drug
NMDAE
drug
lead_sponsor
China Medical University Hospital
company
collaborator
National Science and Technology Council, Taiwan
company
indication
Schizophrenia
indication
Schizophrenia
indication